Product image of Linagliptina/Metformina Sandoz (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptina/Metformina Sandoz

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptina/Metformina Sandoz (Metformin Hydrochloride, Linagliptin)

Linagliptin, the active ingredient in Linagliptina/Metformina Sandoz, is a DPP‑4 inhibitor presented as a tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adults.
GNH India supplies Linagliptina/Metformina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sandoz Farmacéutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptina/Metformina Sandoz is indicated for the management of type 2 diabetes mellitus, acting on glucose regulation pathways.

  • Type 2 diabetes mellitus (monotherapy): improves glycemic control when diet and exercise are insufficient.
  • Type 2 diabetes mellitus (combination therapy): used together with other antidiabetic agents to achieve target HbA1c levels.
  • Adjunct to lifestyle modification: supports blood‑glucose reduction alongside diet and physical activity.

How It Works

  • Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), preventing degradation of endogenous incretin hormones and thereby enhancing glucose‑dependent insulin secretion. Metformin decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity, resulting in lower fasting and post‑prandial glucose concentrations.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, usually transient.
  • Headache: mild tension‑type headaches.
  • Upper respiratory tract infection: nasopharyngitis symptoms.
  • Dizziness: occasional light‑headedness.
  • Abdominal discomfort: mild cramping or bloating.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Hepatic failure: marked liver enzyme elevation.
  • Allergic reactions: rash, angioedema, or anaphylaxis.
  • Renal impairment: worsening kidney function requiring discontinuation.

Precautions & Warnings

Before initiating therapy, assess renal and hepatic function and consider patient‑specific risk factors.

  • Renal function assessment: evaluate eGFR; avoid in severe renal impairment.
  • Hepatic function monitoring: check liver enzymes periodically.
  • Lactic acidosis risk: discontinue if signs of metabolic acidosis appear.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Hypoglycemia monitoring: especially when combined with insulin or sulfonylureas.
  • Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptina/Metformina Sandoz may interact with several drug classes; review patient medication lists.

Major Interactions (Avoid)

  • Iodinated contrast agents: increase risk of metformin‑associated lactic acidosis.
  • Severe renal impairment drugs: contraindicated with other nephrotoxic agents.
  • Cimetidine: may raise metformin plasma concentrations.
  • Strong CYP3A4 inhibitors: can elevate linagliptin levels.
  • Alcohol excess: potentiates metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • Beta‑blockers: can mask hypoglycemia symptoms.
  • ACE inhibitors: monitor blood pressure and renal function.
  • NSAIDs: may impair renal function, increasing metformin exposure.
  • Rifampicin: may reduce linagliptin efficacy.

Frequently Asked Questions

Linagliptina/Metformina Sandoz is a fixed‑dose oral medication indicated for the treatment of type 2 diabetes mellitus. It combines linagliptin, a DPP‑4 inhibitor, with metformin, a biguanide, to improve blood‑glucose control when diet and exercise alone are insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades incretin hormones. By preserving incretins, it enhances glucose‑dependent insulin secretion and reduces glucagon release, helping lower post‑prandial blood glucose levels.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Linagliptina/Metformina Sandoz in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with separate tablets of linagliptin and metformin, the fixed‑dose combination simplifies the regimen, reduces pill burden, and may improve adherence. Unlike sulfonylureas, it has a lower intrinsic risk of hypoglycemia, and unlike some newer agents, it does not require dose titration based on renal function for linagliptin.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include lactic acidosis (particularly in patients with renal impairment), severe hypoglycemia when combined with insulin or sulfonylureas, and pancreatitis. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to linagliptin, metformin, or any excipients, and those with a history of lactic acidosis should avoid this medication. Contraindications must be confirmed by the prescribing clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT